# Risk assessment for cardiovascular adverse drug events in the ICU: Case study on COVID-19 patients

**Authors:** Natalia L. Freitas, Raiane Diniz Oliveira, Ana Katarina da Silva Santos, Marcilio Cunha-Filho, Patricia Medeiros-Souza

PMC · DOI: 10.1371/journal.pone.0345280 · PLOS One · 2026-03-24

## TL;DR

This study assesses cardiovascular risks from drug use in ICU patients with COVID-19 and shows how simulated drug substitutions could significantly reduce these risks.

## Contribution

The novel use of the MedUTI software to simulate drug substitutions and reduce cardiovascular ADE risk in ICU patients is presented.

## Key findings

- Simulated drug substitutions reduced high-risk patients by 53%.
- Optimized prescriptions led to 56% of patients showing medium or low Tisdale scores.
- Cardiovascular ADE medications decreased, including QT prolongation and Torsades de Pointes.

## Abstract

The COVID-19 outbreak quickly became a pandemic. In Brazil, more than seven million cases were recorded in 2020. Most patients affected by the disease were admitted to intensive care units (ICU), requiring qualitative polypharmacy, increasing the risk of serious adverse drug reactions (ADE), especially cardiovascular. This study aimed to identify cardiovascular ADE in the ICU of a reference hospital for the treatment of COVID-19 in Brasília, Brazil. The Tisdale score was determined by analyzing 141 medical records of patients with COVID-19 admitted in 2020. Furthermore, the MedUTI software was used to simulate hypothetical drug substitutions to reduce cardiovascular risk. The result showed that after simulating the hypothetical intervention of prescriptions, a 53% decrease in high-risk patients was observed (from 96.0% to 43.0%). In this optimized prescription condition, 56% of them began to show a Tisdale score of medium or low risk. In addition, a decrease from 67 to 51 of medications with serious cardiovascular ADE was noted, i.e., QT interval prolongation (from 37 to 30), Torsades de Pointes (from 21 to 15), and SS (from 9 to 6). The COVID-19 medical emergency has highlighted the need for rapid medication management in ICU patients. Thus, the use of technologies to support healthcare professionals’ work can be decisive for patient survival, especially in ICU overcrowding scenarios.

## Linked entities

- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, TMPRSS2 (transmembrane serine protease 2) [NCBI Gene 7113] {aka PRSS10}, PPIG (peptidylprolyl isomerase G) [NCBI Gene 9360] {aka CARS-Cyp, CYP, SCAF10, SRCyp}
- **Diseases:** diseases (MESH:D004194), SAH (MESH:D000081029), delirium (MESH:D003693), cardiac impairment (MESH:D006331), sepsis (MESH:D018805), pneumonia (MESH:D011014), visual loss (MESH:D014786), death (MESH:D003643), hypotension (MESH:D007022), depression (MESH:D003866), obese (MESH:D009765), organ dysfunction (MESH:D009102), Torsades de Pointes (MESH:D016171), sudden cardiac death (MESH:D016757), schizophrenia (MESH:D012559), SS (MESH:D020230), AMI (MESH:D009203), infection (MESH:D007239), hearing loss (MESH:D034381), Diabetes mellitus (MESH:D003920), anxiety (MESH:D001007), ototoxic (MESH:D006311), respiratory distress syndrome (MESH:D012128), COVID-19 (MESH:D000086382), arrhythmia (MESH:D001145), renal failure (MESH:D051437), ventricular tachycardias (MESH:D017180), congenital anomalies (MESH:D000013), inflammation (MESH:D007249), critically ill (MESH:D016638), pain (MESH:D010146), hyperglycemia (MESH:D006943), CHF (MESH:D006333), psychosomatic diseases (MESH:D011602), cardiovascular (MESH:D002318), ADE (MESH:D064420), hypertension (MESH:D006973), alcoholism (MESH:D000437), bradycardia (MESH:D001919), QT interval prolongation (MESH:D008133), smoking (MESH:D015208), respiratory diseases (MESH:D012140), mental disorders (MESH:D001523), nausea and vomiting (MESH:D020250)
- **Chemicals:** nortriptyline (MESH:D009661), hydroxychloroquine (MESH:D006886), promethazine (MESH:D011398), amitriptyline (MESH:D000639), tramadol (MESH:D014147), haloperidol (MESH:D006220), azithromycin (MESH:D017963), cyclobenzaprine (MESH:C004704), dexmedetomidine (MESH:D020927), escitalopram (MESH:D000089983), blood glucose (MESH:D001786), clonidine (MESH:D003000), serotonin (MESH:D012701), tacrolimus (MESH:D016559), levomepromazine (MESH:D008728), amiodarone (MESH:D000638), risperidone (MESH:D018967), Methadone (MESH:D008691), morphine (MESH:D009020), antinauseants (-), lopinavir and ritonavir (MESH:C558899), sertraline (MESH:D020280), hydromorphone (MESH:D004091), benzodiazepines (MESH:D001569), potassium (MESH:D011188), ondansetron (MESH:D017294), moxifloxacin (MESH:D000077266), domperidone (MESH:D004294), propofol (MESH:D015742), testosterone (MESH:D013739), propranolol (MESH:D011433), metoclopramide (MESH:D008787), chloroquine (MESH:D002738), fentanyl (MESH:D005283)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13012493/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13012493/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC13012493/full.md

---
Source: https://tomesphere.com/paper/PMC13012493